Plain-English translation of NCT06699394 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our AL Amyloidosis research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a medication called teclistamab in patients with systemic AL amyloidosis—a serious condition where abnormal proteins build up in organs and damage them. Teclistamab is designed to target and destroy the cancer cells producing these harmful proteins. The study hopes to help patients who have already tried other standard treatments without success.
Many patients with AL amyloidosis don't respond well enough to the current first-line treatments, and their condition continues to worsen. This medication is being studied because early evidence suggests it may be more effective at eliminating the cancer cells causing amyloidosis, especially in patients who need additional options.
You likely qualify if…
You likely don't qualify if…
You would receive teclistamab as the single treatment in this study. The exact schedule of visits and how the medication is given will be determined by the research team, but you would be monitored to see how well the treatment works and to check for any side effects. This is a small study enrolling about 20 patients at a medical center in China.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
China